Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.62 |
| ▸ | BCHE | P06276 | 4/20 | 0.62 |
| ▸ | CTSD | P07339 | 11/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 10/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8276492 | 1.00 | BACE1 (0.62) | BACE1BCHECTSDBACE2HTR2A | |
| SCHEMBL3455222 | 1.00 | BACE1 (0.62) | BACE1BCHECTSDBACE2HTR2A | |
| Hydrochloric Acid SCHEMBL2499284 | 0.99 | BACE1 (0.61) | BACE1BCHECTSDBACE2HTR2A | |
| Formic Acid SCHEMBL5928562 | 0.95 | BACE1 (0.60) | BACE1BCHECTSDBACE2HTR2A | |
| SCHEMBL7608334 | 0.91 | BACE1 (0.52) | BACE1BCHECTSDBACE2 | |
| SCHEMBL3343996 | 0.89 | BACE1 (0.56) | BACE1BCHECTSDBACE2HTR2A | |
| SCHEMBL13306695 | 0.89 | BACE1 (0.56) | BACE1BCHECTSDBACE2HTR2A | |
| Hydrochloric Acid SCHEMBL3348081 | 0.88 | BACE1 (0.55) | BACE1BCHECTSDBACE2HTR2A | |
| Hydrochloric Acid SCHEMBL6706412 | 0.88 | BACE1 (0.55) | BACE1BCHECTSDBACE2HTR2A | |
| SCHEMBL5221955 | 0.88 | BACE1 (0.49) | BACE1BCHECTSDBACE2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211740-A1 | Novel compounds | GLAXO GROUP LIMITED | 2006-09-21 | — | — | US | claimed |
| JP-2004502669-A | — | — | 2004-01-29 | — | — | JP | claimed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| EP-4153561-B1 | 9H-FLUOREN DERIVATES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | UNIV JAGIELLONSKI (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-12492163-B2 | 9H-fluorene derivatives or their pharmaceutically acceptable salts | UNIWERSYTET JAGIELLONSKI (PL) | 2025-12-09 | — | — | US | disclosed |
| US-20230117233-A1 | NOVEL 9H-FLUORENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | UNIWERSYTET JAGIELLONSKI (PL) | 2023-04-20 | — | — | US | disclosed |
| EP-4153561-A2 | 9H-FLUOREN DERIVATES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | UNIWERSYTET JAGIELLONSKI (PL) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021235956-A2 | NOVEL 9H-FLUORENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | Uniwersytet Jagielloński (PL) | 2021-11-25 | — | — | WO | disclosed |
| WO-2017066742-A1 | BACE-2 INHIBITORY COMPOUNDS AND RELATED METHODS OF USE | JORTAN PHARMACEUTICALS INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066742-A1 | BACE-2 INHIBITORY COMPOUNDS AND RELATED METHODS OF USE | JORTAN PHARMACEUTICALS INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20060211740-A1 | Novel compounds | GLAXO GROUP LIMITED | 2006-09-21 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1611089-A2 | HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004080376-A2 | HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | BACE1 4/4885BCHE 12/4885CTSD 2080/4885 |
| US-20230117233-A1 | NOVEL 9H-FLUORENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | BACE1, BACE2, APP | BACE1 1/4885BCHE 4/4885CTSD 37/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | BACE1 3/4885BCHE 11/4885CTSD 384/4885 |
| US-20060211740-A1 | Novel compounds | BACE2, BACE1, PSEN2 | BACE1 2/4885BCHE 24/4885CTSD 366/4885 |
| US-12492163-B2 | 9H-fluorene derivatives or their pharmaceutically acceptable salts | BACE1, BACE2, APP | BACE1 1/4885BCHE 5/4885CTSD 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.